Fundraising FoxLongwood Fund — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
BiotechBoston, US
David Donabedian(Executive Officer, Director)inRobert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardMing Cheah(Director)inRaymond Camahort(Director)
Board seatChristoph Westphal· per SEC Form D
Co-investorsDCVC (Data Collective)DCVC BioArkin CapitalNovo Holdings
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsDelos CapitalForesite CapitalINCE CapitalNew Enterprise Associates (NEA)OrbiMedQuan Capital+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.